Search results
UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Reuters via Yahoo Finance· 6 days agoMerck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling ...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 6 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 6 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 6 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
British patients test world’s first personalised mRNA jab for melanoma
PA Media: Science via Yahoo News· 5 days agoPhase 2 data, published in December, found that people with serious high-risk melanomas who received...
Man’s ‘bump on head’ turns out to be sign of skin cancer
Yahoo Life UK· 5 days agoYoung says he feels 'excited' to be trialling the new vaccine. (PA) PA Phase 2 data, published in...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 5 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days ago- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase ...
British man tests first personalised melanoma vaccine
BBC via Yahoo News· 5 days agoPhase II trial data, published in December, found that people with serious high-risk melanomas who...
Bristol-Myers stock falls despite Q1 beat (NYSE:BMY)
Seeking Alpha· 6 days agoBristol-Myers Squibb (BMY) stock dips even as the company topped consensus with Q1 2024 results, despite headwinds in its growth portfolio. Read more...